Inventor · disambiguated record
Peter Schafer
Also filed as: SCHAEFER PETER · SCHAFER PETER · SCHAFER PETER H · SCHAFER PETER HENRY
122 granted patents·93 pending applications·971 citations·filing 1994–2024
99Inventor score
Top patents by PatentIndex Score
215 records- 0199US7893101B2Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereofCELGENE CORP·Filed 2008·Granted Feb 22, 2011·44 cites·15 claims
- 0298US7427638B2(+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione:, and methods of synthesis and compositions thereofCELGENE CORP·Filed 2005·Granted Sep 23, 2008·53 cites·13 claims
- 0398US6962940B2(+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereofCELGENE CORP·Filed 2003·Granted Nov 8, 2005·107 cites·23 claims
- 0497US8455536B2Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline 1,3-dioneMULLER GEORGE W·Filed 2009·Granted Jun 4, 2013·28 cites·56 claims
- 0597US7659302B2Methods of using (+)-2-[1-(3-ethoxy-4 methoxyphenyl)-2-methylsulfonylethyl]-4 acetylaminoisoindoline 1,3-dioneCELGENE CORP·Filed 2008·Granted Feb 9, 2010·35 cites·20 claims
- 0696US10047151B2Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictorCELGENE CORP·Filed 2016·Granted Aug 14, 2018·19 cites·5 claims
- 0796US9018243B2Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereofCELGENE CORP·Filed 2013·Granted Apr 28, 2015·13 cites·21 claims
- 0896US8093283B2Solid forms comprising (+)-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisinoline-1,3-dione, compositions thereof, and uses thereofMULLER GEORGE W·Filed 2010·Granted Jan 10, 2012·17 cites·42 claims
- 0996US7659303B2Methods of using (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4- acetylaminoisoindoline-1,3-dioneCELGENE CORP·Filed 2008·Granted Feb 9, 2010·21 cites·14 claims
- 1096US7507759B2Methods of using(+)-2-[1-(3-ethoxy-4methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3,-dioneCELGENE CORP·Filed 2007·Granted Mar 24, 2009·21 cites·11 claims
- 1196US7358272B2Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4 acetylaminoisoindoline 1,3-dioneCELGENE CORP·Filed 2005·Granted Apr 15, 2008·21 cites·17 claims
- 1296US7208516B2Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dioneCELGENE CORP·Filed 2006·Granted Apr 24, 2007·40 cites·18 claims
- 1395US8802717B2Methods of treating arthritic conditions using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline 1,3-dioneCELGENE CORP·Filed 2012·Granted Aug 12, 2014·13 cites·22 claims
- 1495US8629173B2Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereofMULLER GEORGE W·Filed 2011·Granted Jan 14, 2014·11 cites·39 claims
- 1595US8008232B2Pyrazolecarboxanilides, process for their preparation and compositions comprising them for controlling harmful fungiBASF AG·Filed 2006·Granted Aug 30, 2011·17 cites·9 claims
- 1695US7276529B2Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dioneCELGENE CORP·Filed 2006·Granted Oct 2, 2007·28 cites·15 claims
- 1794US9724330B2Methods of using (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dioneCELGENE CORP·Filed 2016·Granted Aug 8, 2017·7 cites·33 claims
- 1893US6455515B2Salicylohydrazide derivatives, processes and intermediates for their preparation, compositions comprising them, and their useBASF AG·Filed 2001·Granted Sep 24, 2002·41 cites·6 claims
- 1992US6362380B1Preparation of nitrobiphenylsBASF AG·Filed 2000·Granted Mar 26, 2002·25 cites·21 claims
- 2091US10092542B2Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dioneCELGENE CORP·Filed 2017·Granted Oct 9, 2018·4 cites·17 claims
- 2191US9283207B2Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dioneCELGENE CORP·Filed 2014·Granted Mar 15, 2016·7 cites·24 claims
- 2291US8906932B2Methods of treating cancer using 3-(5-amino-2-methyl-4-oxo-4Hquinazolin-3-yl)-piperidine-2,6-dioneMULLER GEORGE W·Filed 2012·Granted Dec 9, 2014·15 cites·27 claims
- 2390US11660302B23-(4-((4-(morpholinomethyl-benzyl)oxy)-1 -oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosusCELGENE CORP·Filed 2021·Granted May 30, 2023·1 cites·18 claims
- 2490US10980812B23-(4-((4-(morpholinomethyl-benzyl)oxy)-1 -oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosusCELGENE CORP·Filed 2020·Granted Apr 20, 2021·2 cites·19 claims
- 2590US10018637B2Methods for treating inflammatory and other diseases and the use of biomarkers as predictors of clinical sensitivity to treatment with apremilastCELGENE INT II SARL·Filed 2016·Granted Jul 10, 2018·7 cites·19 claims
- 2690US9857359B2Methods for determining drug efficacy using cereblon-associated proteinsCELGENE CORP·Filed 2013·Granted Jan 2, 2018·11 cites·15 claims
- 2790US9433606B2Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereofCELGENE CORP·Filed 2015·Granted Sep 6, 2016·3 cites·15 claims
- 2890US9365640B2Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictorLOPEZ-GIRONA ANTONIA·Filed 2012·Granted Jun 14, 2016·16 cites·19 claims
- 2989US8715677B2Immunological uses of immunomodulatory compounds for vaccine and anti-infectious disease therapyBARTLETT JUSTIN B·Filed 2006·Granted May 6, 2014·48 cites·15 claims
- 3087US10751414B2Methods of treating psoriasis using PD-1 binding antibodiesCELGENE CORP·Filed 2017·Granted Aug 25, 2020·9 cites·66 claims
- 3187US10610516B2Methods of using (+)- 2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1, 3-dioneAMGEN INC·Filed 2018·Granted Apr 7, 2020·1 cites·15 claims
- 3287US7799334B2PyrazolecarboxamidesBASF AG·Filed 2006·Granted Sep 21, 2010·4 cites·11 claims
- 3384US10245266B23-(4-((4-morpholinomethyl-benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosusCELGENE CORP·Filed 2015·Granted Apr 2, 2019·3 cites·16 claims
- 3484US7501383B2Substituted [1,2,4]triazolo[1,5-a]pyrimidines and their use for controlling harmful fungiBASF AG·Filed 2005·Granted Mar 10, 2009·4 cites·10 claims
- 3583US2024041894A13-(4-((4-(morpholinomethyl-benzyl)oxy)-1 -oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosusCELGENE CORP·Filed 2023·Application pending·0 cites
- 3682US6191280B1Method for producing substituted thiopyridinesBASF AG·Filed 1998·Granted Feb 20, 2001·30 cites·4 claims
- 3781US7820647B22-substituted pyrimidines and their use as pesticidesBASF AG·Filed 2005·Granted Oct 26, 2010·3 cites·9 claims
- 3880US10596179B23-(4-((4-morpholinomethyl-benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosusCELGENE CORP·Filed 2019·Granted Mar 24, 2020·1 cites·20 claims
- 3978US11260046B2(+)-2-[1-(3-Ethoxy-4- methoxyphenyl)-2-methylsulfonylethyl]- 4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereofAMGEN INC·Filed 2020·Granted Mar 1, 2022·0 cites·7 claims
- 4077US7695728B22-substituted pyridines, processes for their preparation and their use for controlling harmful fungiBASF AG·Filed 2005·Granted Apr 13, 2010·1 cites·11 claims
- 4177US6855718B27-(r)-aminotriazolopyrimidines, the production thereof and use of the same for combatting phytopathogenic fungiBASF AG·Filed 2001·Granted Feb 15, 2005·6 cites·8 claims
- 4277US6552026B26-phenyl-pyrazolopyrimidinesBASF AG·Filed 2000·Granted Apr 22, 2003·7 cites·9 claims
- 4376US11040024B2Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dioneAMGEN INC·Filed 2020·Granted Jun 22, 2021·0 cites·5 claims
- 4476US7449471B25-phenylpyrimidines, their preparation, compositions comprising them and their useBASF AG·Filed 2007·Granted Nov 11, 2008·1 cites·2 claims
- 4576US7153860B25-Phenylpyrimidines, methods and intermediate products for the production thereof and use of the same for controlling pathogenic fungiBASF AG·Filed 2002·Granted Dec 26, 2006·6 cites·8 claims
- 4674US7786043B22-(pyridin-2-yl)-pyrimidines and their use for controlling harmful fungiBASF AG·Filed 2005·Granted Aug 31, 2010·1 cites·13 claims
- 4773US11357775B2Combination therapies comprising apremilast and Tyk2 inhibitorsCELGENE CORP·Filed 2019·Granted Jun 14, 2022·1 cites·20 claims
- 4873US2025032502A1Methods for treating systemic lupus erythematosus and the use of biomarkers as a predictor of clinical sensitivity to therapiesCELGENE CORP·Filed 2024·Application pending·0 cites
- 4972US2023159490A1Treatment of immune-related and inflammatory diseasesCELGENE CORP·Filed 2022·Application pending·0 cites
- 5071US6624119B13-[Benz(ox/thi)azol-7-yl]-1h-pyrimidine-2,4-dionesBASF AG·Filed 1999·Granted Sep 23, 2003·18 cites·10 claims
Showing the top 50 of 215 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →